Nowadays, the standard-of-care (SOC) treatment options of advanced stage (IIb and IV) solid cancers (e.g., lung, breast , colon cancer) include different therapeutic options, ranging from standard chemotherapies to novel targeted therapeutics or immunotherapies.


As of the onset of first-line therapy, the patient is periodically assessed (typically every 2-4 months) to evaluate the state of the disease and the efficacy of the treatment. Disease progression is determined according to the Response Evaluation Criteria In Solid Tumors )RECIST) 1.1, which are clinically apparent significant or abrupt increases in the total tumor burden (composed of the tumor lesions’ longest diameters), and/or appearance of new lesions that might appear in different organs (e.g. brain, bones, liver) and worsen the disease. 


Once progression is identified, the physician stops the current treatment and switches to the next-line therapeutic, selected again from several SOC optional protocols. Yet, the increase in tumor load or extent of its invasion, coupled with the declining patient constitution, renders the next-line treatment more challenging than previously. Hence, there is a vital need to enable clinicians to switch to the next-line of therapy prior to major deterioration in the patient's disease state. This can be done by providing clinicians with the capacity to predict imminent progression before it is clinically detected.